Alterations in Cytokine Profile and Dendritic Cells Subsets in Peripheral Blood of Rheumatoid Arthritis Patients before and after Biologic Therapy
- 1 September 2009
- journal article
- clinical trial
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1173 (1) , 334-342
Abstract
Rheumatoid arthritis (RA) is an autoimmune disorder characterized by chronic joint inflammation and continuous immune cell infiltration in the synovium. These changes are linked to inflammatory cytokine release, leading to eventual destruction of cartilage and bone. During the last decade new therapeutic modalities have improved the prognosis, with the introduction of novel biological response modifiers including anti‐TNFα CTLA4Ig and, more recently, anti‐IL6. In the present study we looked at the immunological effects of these three forms of therapy. Serum, obtained from patients with RA was analyzed for TNFα, IL6, IL10, IFNγ, and VEGF, and in parallel, circulating plasmacytoid and myeloid dendritic cells (DC) were enumerated before and after three infusions of the respective biological treatments. After treatment with anti‐IL6, we found a significant reduction of IL6 and TNFα levels and the percentage of both DC subsets decreased. Although the results did not reach statistical significance for anti‐TNFα treatment, similar trends were observed. Meanwhile, CTLA4Ig therapy led to the reduction IFNγ levels only. None of the treatments modified significantly VEGF or IL10 levels. These findings may explain why patients with RA improve more rapidly on IL‐6 therapy than with the other two modalities.Keywords
This publication has 32 references indexed in Scilit:
- RADIATE: more treatment options for patients with an inadequate response to tumor necrosis factor antagonistsNature Clinical Practice Rheumatology, 2008
- Co-stimulatory modulation in rheumatoid arthritis: The role of (CTLA4-Ig) abataceptAutoimmunity Reviews, 2008
- The importance of the baseline Disease Activity Score 28 in determining responders and non-responders to anti-TNF in UK clinical practiceRheumatology, 2008
- Abatacept: the first T lymphocyte co-stimulation modulator, for the treatment of rheumatoid arthritisExpert Opinion on Biological Therapy, 2007
- Abatacept: a costimulatory inhibitor for treatment of rheumatoid arthritisExpert Opinion on Biological Therapy, 2005
- Role of plasmacytoid dendritic cells in immunity and tolerance after allogeneic hematopoietic stem cell transplantationTransplant Immunology, 2003
- Inhibition of the production and effects of interleukins‐1 and tumor necrosis factor α in rheumatoid arthritisArthritis & Rheumatism, 1995
- Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis & Rheumatism, 1995
- Interleukin-6 Antibodies in Rheumatoid ArthritisJournal of Interferon Research, 1994
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988